HHC
KIN

Hutchin Hill Capital’s Kindred Biosciences, Inc. KIN Stock Holding History

Hutchin Hill Capital’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-11,719
Closed -$131K – 760
2013
Q4 		$131K Buy
+11,719
New +$140K 0.01% 492

Other funds holding KIN

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Hutchin Hill Capital's KIN Position: Q1 2014 in Review

Hutchin Hill Capital sold out of Kindred Biosciences, Inc. (KIN) in Q1 2014, closing a stake of 11,719 shares — an estimated $131K sold.

Hutchin Hill Capital first reported a position in KIN in Q4 2013 and held it in 1 quarter. The position peaked at $131K in Q4 2013. 39 funds tracked by Wall St. Rank hold KIN as of Q1 2014.

  • Hutchin Hill Capital reported no remaining Kindred Biosciences, Inc. position as of Q1 2014 after selling out during the quarter.
  • Hutchin Hill Capital sold 11,719 Kindred Biosciences, Inc. shares in Q1 2014, an estimated $131K.
  • Hutchin Hill Capital first reported a position in Kindred Biosciences, Inc. in Q4 2013 and held it in 1 quarter.
  • Hutchin Hill Capital's Kindred Biosciences, Inc. position peaked at $131K in Q4 2013.
  • 39 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q1 2014.

Based on Hutchin Hill Capital's 13F filing for Q1 2014, filed 15 May 2014.